NCT00799331已完成1 期
An Exploratory Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Pharmacokinetics of Increasing Oral Doses of AZD5985 in Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- It is the objective of this exploratory study to assess pharmacokinetics of AZD5985 following administration of single increasing doses. The primary variable is plasma concentration of AZD5985.
研究概览
简要总结
The aim of this exploratory study is to assess the pharmacokinetics of increasing oral doses of AZD5985 in healthy male volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Provision of signed, written and dated informed consent prior to any study specific procedures.
- •Healthy male subjects aged 18 to 45 years (inclusive).
- •Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg.
- •Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for >6 months prior to study start.
排除标准
- •History or presence of any clinically significant disease or disorder in the opinion of the investigator.
- •Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs or ECG at baseline in the opinion of the investigator.
- •Participation in another investigational drug study within 3 months before Visit 2 or participation in a method development study (no drug) 1 month prior to Visit 2
研究组 & 干预措施
A
Experimental
AZD5985
干预措施: AZD5985 (Drug)
B
Experimental
placebo
干预措施: placebo (Drug)
结局指标
主要结局
It is the objective of this exploratory study to assess pharmacokinetics of AZD5985 following administration of single increasing doses. The primary variable is plasma concentration of AZD5985.
时间窗: Frequent sampling occasions during study days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of an Extended Release (ER) Tablet, Single and Repeated DosingHealthyNCT00689039AstraZeneca94
已完成
1 期
A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood LevelsHealthyNCT01069822AstraZeneca46
已完成
1 期
Safety Study of AZD5672 in Renally Impaired SubjectsRenal ImpairmentNCT00715702AstraZeneca40
已完成
1 期
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451Bipolar DisorderNCT01196676AstraZeneca63
已完成
1 期
A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722HealthyNCT02346890Ardelyx16